Restrictions in use of cyproterone acetate due to risk of meningioma
About
This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.
Documents
Key facts
| Active substance |
cyproterone
|
| Therapeutic area (MeSH) |
Androgen Antagonists
|
| Procedure number |
EMEA/H/A-31/1488
|
| Regulatory outcome |
Variation
|
| DHPC type |
Referral - Article 31
|
| Referral name |
Cyproterone-containing medicinal products
|